Literature DB >> 31259501

Polypharmacy: Evaluating Risks and Deprescribing.

Anne D Halli-Tierney1, Catherine Scarbrough2, Dana Carroll3.   

Abstract

Polypharmacy, defined as regular use of at least five medications, is common in older adults and younger at-risk populations and increases the risk of adverse medical outcomes. There are several risk factors that can lead to polypharmacy. Patient-related factors include having multiple medical conditions managed by multiple subspecialist physicians, having chronic mental health conditions, and residing in a long-term care facility. Systems-level factors include poorly updated medical records, automated refill services, and prescribing to meet disease-specific quality metrics. Tools that help identify potentially inappropriate medication use include the Beers, STOPP (screening tool of older people's prescriptions), and START (screening tool to alert to right treatment) criteria, and the Medication Appropriateness Index. No one tool or strategy has been shown to be superior in improving patient-related outcomes and decreasing polypharmacy risks. Monitoring patients' active medication lists and deprescribing any unnecessary medications are recommended to reduce pill burden, the risks of adverse drug events, and financial hardship. Physicians should view deprescribing as a therapeutic intervention similar to initiating clinically appropriate therapy. When deprescribing, physicians should consider patient/ caregiver perspectives on goals of therapy, including views on medications and chronic conditions and preferences and priorities regarding prescribing to slow disease progression, prevent health decline, and address symptoms. Point-of-care tools can aid physicians in deprescribing and help patients understand the need to decrease medication burden to reduce the risks of polypharmacy.

Entities:  

Mesh:

Year:  2019        PMID: 31259501

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  36 in total

1.  The Potential Contribution of Chronic Pain and Common Chronic Pain Conditions to Subsequent Cognitive Decline, New Onset Cognitive Impairment, and Incident Dementia: A Systematic Review and Conceptual Model for Future Research.

Authors:  Kim E Innes; Usha Sambamoorthi
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

2.  A survey of internists' recommendations for aspirin in older adults and barriers to evidence-based use.

Authors:  Jordan K Schaefer; Geoffrey D Barnes; Jeremy B Sussman; Sameer D Saini; Tanner J Caverly; Susan Read; Brian J Zikmund-Fisher; Jacob E Kurlander
Journal:  J Thromb Thrombolysis       Date:  2022-06-14       Impact factor: 2.300

Review 3.  Polypharmacy in elderly people.

Authors:  Peter Dovjak
Journal:  Wien Med Wochenschr       Date:  2022-01-10

4.  Deprescribing Inappropriate Proton Pump Inhibitors in a Family Medicine Residency Practice Office.

Authors:  Andrew Lai; Amy Odom; Steven E Roskos; Julie P Phillips
Journal:  PRiMER       Date:  2021-11-02

5.  Evaluating the impact of a polypharmacy Action Learning Sets tool on healthcare practitioners' confidence, perceptions and experiences of stopping inappropriate medicines.

Authors:  Cindy Faith Brooks; Anastasios Argyropoulos; Catherine Brigitte Matheson-Monnet; David Kryl
Journal:  BMC Med Educ       Date:  2022-06-27       Impact factor: 3.263

6.  Analysis of interaction risks of patients with polypharmacy and the pharmacist interventions performed to solve them-A multicenter descriptive study according to medication reviews in Hungarian community pharmacies.

Authors:  András Szilvay; Orsolya Somogyi; Annamária Dobszay; Attiláné Meskó; Romána Zelkó; Balázs Hankó
Journal:  PLoS One       Date:  2021-06-22       Impact factor: 3.240

7.  Statin nonadherence in Latino and noncitizen neighborhoods in New York City, Los Angeles, and Chicago, 2012-2016.

Authors:  Jenny S Guadamuz; Ramon A Durazo-Arvizu; Martha L Daviglus; Gregory S Calip; Edith A Nutescu; Dima M Qato
Journal:  J Am Pharm Assoc (2003)       Date:  2021-02-23

8.  Successful deprescribing of proton pump inhibitors with a patient-centered process: the DESPIBP Project.

Authors:  Lamuela L J Calvo; P García Cámara; M Llorente Barrio; O Sierra Gabarda; R Monzón Baez; J M Arbonés Mainar; J Alcedo González; V Bernal Monterde
Journal:  Eur J Clin Pharmacol       Date:  2021-07-16       Impact factor: 2.953

Review 9.  Deprescribing for all: a narrative review identifying inappropriate polypharmacy for all ages in hospital settings.

Authors:  Ali Elbeddini; Monakshi Sawhney; Yasamin Tayefehchamani; Zekiye Yilmaz; Ahmed Elshahawi; Josiah Josh Villegas; Janelyn Dela Cruz
Journal:  BMJ Open Qual       Date:  2021-07

10.  Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia.

Authors:  Prajwal Dhakal; Elizabeth Lyden; Kate-Lynn E Muir; Zaid S Al-Kadhimi; Thuy Koll; Lori J Maness; Krishna Gundabolu; Vijaya Raj Bhatt
Journal:  Leuk Lymphoma       Date:  2020-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.